Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04951154 · ClinicalTrials.gov registry record
A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer
A clinical trial of Carcinoma, Non-Small Cell Lung, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 33
- Enrollment target
- 2
- Study locations
NCT04951154 is a study of Carcinoma, Non-Small Cell Lung that has completed, run by Janssen Research & Development. The registered enrollment target is 33 participants, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (90% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04951154, a study of Carcinoma, Non-Small Cell Lung, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to assess spontaneous residual viable tumor cells (RVT) in the surgically resected tumor (Non-small cell lung cancer \[NSCLC\]).
Conditions Studied
Interventions
- OTHER Blood Sample
- OTHER Bronchoscopic Biopsy
Study Locations (2)
District of Columbia
- Medstar Washington Hospital Center - Washington D.C.
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2023-05-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04951154
The ClinicalTrials.gov registry entry for NCT04951154 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 324-participant average among 130 other Carcinoma, Non-Small Cell Lung trials with a reported enrollment target (90% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Non-Small Cell Lung appearing as the primary indexed condition, and to 2 interventions - of which Blood Sample is the first listed.
NCT04951154 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New York.
Frequently Asked Questions
What is clinical trial NCT04951154 about?
NCT04951154 is a clinical study titled "A Study to Examine Biomarkers From Lung and Blood Samples in Participants With Suspected Lung Cancer". The purpose of this study is to assess spontaneous residual viable tumor cells (RVT) in the surgically resected tumor (Non-small cell lung cancer \[NSCLC\]).
What is the current status of trial NCT04951154?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2022-03-28. Estimated completion is 2023-05-15.
What conditions does trial NCT04951154 study?
This clinical trial studies the following conditions: Carcinoma, Non-Small Cell Lung.
What interventions are being tested in trial NCT04951154?
The interventions under investigation include: Blood Sample (OTHER), Bronchoscopic Biopsy (OTHER).
Who is sponsoring clinical trial NCT04951154?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04951154 being conducted?
This trial has 2 study locations across District of Columbia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Non-Small Cell Lung
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
RECRUITING · Phase 1
-
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RECRUITING · Phase 1
-
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 3
-
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.